Unicycive Therapeutics Inc. · 완전응답서한 (NDA 218607)

출처 발췌

¢ yy U.S. FOOD & DRUG ADMINISTRATION NDA 218607 COMPLETE RESPONSE Unicycive Therapeutics Inc. Attention: Shalabh Gupta, MD, MPA President & CEO 1975 W. El Camino Real, Suite 204 Mountain View, CA 94040 Dear Dr. Gupta: Please refer to your new drug application (NDA) dated and received August 28, 2024, and your amendments, submitted pursuant to for oxylanthanum carbonate tablets. We acknowledge receipt of your amendment dated December 29, 2025, which constituted a complete response to our June 27, 2025, action letter. We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues. FACILITY

openFDA